Tilray’s stock has fallen more than 90% from its 2018 highs. It now trades as a penny stock. So it’s a fair question — is this company actually on its way out?
The honest answer is: not necessarily, but the situation is genuinely serious. A collapsing share price and a dying business are two different things, and it’s worth separating them clearly.
This article covers what Tilray actually looks like today, why the stock crashed so hard, the real state of its finances, what delisting would mean in practice, and what plausible paths forward exist.
What Tilray Is Today
A lot of people still think of Tilray as a pure cannabis company. That hasn’t been accurate for a while.
Tilray Brands, Inc. is now a diversified consumer goods and pharmaceutical company headquartered in New York. It was formed through a 2021 merger with Aphria, which at the time created one of the largest cannabis companies by revenue in the world.
Today, its revenue comes from four main areas:
- Cannabis: roughly 35% of revenue
- Craft beer and alcohol: roughly 25%
- European pharmaceutical distribution (including medical cannabis): roughly 33%
- Hemp-based wellness foods (like Manitoba Harvest): roughly 7%
The company is still listed on both NASDAQ and the Toronto Stock Exchange. It still employs thousands of people. It’s still generating revenue across multiple business lines.
None of that sounds like a company that has already shut down. But “still operating” and “financially healthy” are also very different things.
Why the Stock Has Fallen More Than 90%
TLRY shares are down roughly 92% from their 2018 peak. That number sounds catastrophic — and for shareholders, it is. But it doesn’t automatically mean the business has ceased to function.
Think of it this way: if a house loses most of its market value, the house doesn’t disappear. The owner’s equity is severely damaged, but the structure is still standing. The same logic applies here.
Several factors drove the collapse:
- Cannabis oversupply in Canada. Too much product, too little pricing power.
- Slow U.S. federal legalization. The market that was supposed to open hasn’t.
- High taxes and competition from the illicit market. Legal cannabis can’t always compete on price with unregulated supply.
- Weak industry margins across the board. This is a sector-wide problem, not just Tilray’s.
Tilray was also treated as a meme stock for a period. That meant speculative run-ups followed by sharp reversals, which amplified both the highs and the crashes.
A short seller report also accused Tilray management of malfeasance, which added to negative investor sentiment. It’s worth being clear: these are allegations, not proven findings. But even unproven allegations can hurt a company’s access to capital and erode investor confidence — and that has real consequences.
The Actual Financial Condition
Tilray reported a net loss of approximately $1.4 billion for fiscal year 2023. That’s a large number, but context matters.
A significant portion of that loss came from intangible asset write-downs — essentially accounting adjustments tied to acquisitions, not cash walking out the door. A company writing down the value of assets it overpaid for is painful, but it’s different from running out of money today.
The company continues to generate revenue across its segments. Losses on paper are not the same as immediate insolvency.
That said, the financial position is genuinely stressed. Heavy debt, ongoing unprofitability, and a depressed stock price all make future capital raises expensive and difficult. When a company needs to borrow or issue shares to stay afloat, doing so from a position of weakness costs more.
As of the sources used for this article, there is no widely reported bankruptcy filing or formal going-concern notice from Tilray’s auditors. But this is a time-sensitive situation. Anyone making financial decisions around TLRY should check the most recent 10-Q or 10-K filing for updated cash levels, debt obligations, and any auditor language about the company’s ability to continue operating.
Financially distressed and insolvent are not the same category. Tilray appears to be in the first group. Whether it stays there or slides into the second depends on decisions being made right now.
Delisting Risk Is Real — But It Doesn’t Mean Shutdown
As a penny stock on NASDAQ, Tilray faces a real risk of being delisted. NASDAQ requires companies to maintain a minimum bid price — typically $1 per share, sustained over time. When a stock trades below that threshold consistently, the exchange can issue a deficiency notice and eventually remove the company from the listing.
One reason Tilray has been pushing its beer and consumer packaged goods pivot so aggressively is partly to diversify revenue and signal viability. A company with multiple revenue streams looks more stable than one entirely dependent on a struggling sector.
If Tilray were delisted, it could still continue to trade on OTC (over-the-counter) markets. It could still pay employees, sell products, and operate. Being removed from NASDAQ is like being moved from a major stock exchange to a smaller venue — it’s a reputational and practical setback, but it is not the same as closing the business.
Companies can and do survive delisting. It limits institutional investor access and raises borrowing costs, but operations don’t automatically stop. Tilray could also pursue a reverse stock split to artificially raise its share price above the minimum threshold — a common tactic, though one that doesn’t fix the underlying business problems.
What the Beer Pivot Actually Means
Tilray’s acquisition of craft beer brands has been described by management as a strategic pivot toward a diversified consumer goods company. The idea is that beer and cannabis share some distribution and retail infrastructure, and that building a CPG presence now could position the company well if U.S. federal cannabis laws eventually change.
That’s a reasonable strategic argument. The question is whether it’s a well-planned evolution or a scramble for survival dressed up in strategy language.
Cannabis oversupply and price compression in Canada are structural problems that aren’t going away quickly. Beer gives Tilray a revenue line that doesn’t depend on cannabis policy or illicit market competition in the same way. The pharmaceutical distribution arm in Europe adds another layer of stability.
Whether these moves are enough to turn the business profitable is genuinely uncertain. The company has spent heavily on acquisitions, carries significant debt, and is still posting large net losses. Diversification buys time. It doesn’t automatically fix the balance sheet.
What “Going Out of Business” Would Actually Look Like
It’s worth being specific about what the different outcomes here actually mean:
- Bankruptcy or insolvency: A formal filing under Chapter 11 or Canadian creditor protection. This involves court-supervised restructuring or liquidation. As of the latest available information, this has not happened.
- Delisting: Removal from NASDAQ, possibly followed by OTC trading. Operations could continue. This is a real risk given the penny stock status.
- Acquisition or merger: A larger company buys Tilray’s assets or takes over the entity. This is a plausible scenario if the stock stays depressed and the asset base retains value.
- Slow restructuring: Asset sales, cost-cutting, segment divestitures — a gradual shrinking rather than a sudden collapse.
None of these scenarios involve Tilray simply “going out of business” in the overnight sense that the phrase implies. The real risks are more gradual and more complicated than that framing suggests.
For a broader look at how distressed businesses navigate situations like this, Young Business Mag covers practical business strategy and case studies worth following.
What This Means in Practice
Tilray is not a healthy company. It has posted massive losses, carries heavy debt, trades as a penny stock, and operates in a sector facing real structural challenges. None of that should be minimized.
But “struggling seriously” and “going out of business” are different conclusions. The company still has revenue, employees, multiple business lines, and an exchange listing — for now.
The path forward depends on whether management can stabilize the balance sheet, whether the diversification into beer and pharma produces real profitability, and whether any positive shift in U.S. cannabis policy eventually provides a tailwind.
Those are genuine uncertainties, not guarantees in either direction. Anyone watching this company — whether as an investor, a competitor, or just someone following the cannabis sector — should track the actual financials rather than the stock price alone. The share price got the headlines. The balance sheet will determine what actually happens next.
Read Also:
